← Back to patent-cliff list
TQ-B3234
Tier C — Watch / tradeTQ-B3234
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MEK2, MEK1
Indications (approved)：Plexiform neurofibroma, Neurofibromatosis type I, Neoplasm, 神经纤维瘤, Schwannoma
Regional status
US
-
EU
-
China
Phase III
2026-03-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TQ-B3234?
Approved indications include: Plexiform neurofibroma, Neurofibromatosis type I, Neoplasm, 神经纤维瘤, Schwannoma.
When does the TQ-B3234 patent expire?
No public expiry year is available for TQ-B3234 yet; this page updates once verified.
How do I get a quote for TQ-B3234 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29